Alterity Therapeutics Ltd.ASX: ATH

Disclosure Under Takeovers Panel GN 20

Aug 17, 2026 at 12:52 AM EDT · Issued by Alterity Therapeutics Ltd. via ASX

Filed with ASX · Aug 17, 2026 at 12:52 AM EDT

On 6ix: 6ix.com/news/disclosure-under-takeovers-panel-gn-20

Alterity Therapeutics Limited ACN 080 699 065 Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia www.alteritytx.com ASX ANNOUNCEMENT 17 August 2026 Disclosure under Takeovers Panel Guidance Note 20: Equity Derivatives Alterity Therapeutics Limited ACN...

View Attachment

6ix hasn’t read this filing yet.

Alterity Therapeutics Ltd. on 6ix

Earlier from Alterity Therapeutics

Application for quotation of securities - ATHAug 14
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434Aug 12
Granted New U.S. Composition of Matter Patent for ATH434Aug 11
Alterity to Present at Canaccord Genuity Growth ConferenceAug 5
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate UpdateJul 30

Later from Alterity Therapeutics

Appendix 4GAug 28
Corporate Governance StatementAug 28
Appendix 4E and 2026 Annual ReportAug 28
$4.2M Options Underwriting Agreement ExecutedAug 30
Alterity Therapeutics Filed Form 20-F and XBRL Data with SECAug 30

All Alterity Therapeutics news releases

Follow Alterity Therapeutics into a list and get an email when it puts out news.

Follow Alterity Therapeutics